These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy? Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266 [TBL] [Abstract][Full Text] [Related]
3. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Khosla N; Kalaitzidis R; Bakris GL Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132 [TBL] [Abstract][Full Text] [Related]
5. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Mahmud A; Mahgoub M; Hall M; Feely J Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838 [TBL] [Abstract][Full Text] [Related]
6. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153 [TBL] [Abstract][Full Text] [Related]
7. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242 [TBL] [Abstract][Full Text] [Related]
8. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Lim PO; Jung RT; MacDonald TM Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479 [TBL] [Abstract][Full Text] [Related]
9. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564 [TBL] [Abstract][Full Text] [Related]
10. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol. Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623 [TBL] [Abstract][Full Text] [Related]
11. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment. Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481 [TBL] [Abstract][Full Text] [Related]
12. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989 [TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension. Rossi GP; Maiolino G Hypertens Res; 2014 Dec; 37(12):1029-31. PubMed ID: 25231253 [No Abstract] [Full Text] [Related]
14. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266 [TBL] [Abstract][Full Text] [Related]
16. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. de Haro Moraes C; Figueiredo VN; de Faria AP; Barbaro NR; Sabbatini AR; Quinaglia T; Ferreira-Melo SE; Martins LC; Demacq C; Júnior HM J Hum Hypertens; 2013 Apr; 27(4):225-30. PubMed ID: 22810172 [TBL] [Abstract][Full Text] [Related]
17. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826 [TBL] [Abstract][Full Text] [Related]
18. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822 [TBL] [Abstract][Full Text] [Related]
19. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101 [TBL] [Abstract][Full Text] [Related]
20. The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis. Elnagar N; Satoh M; Hosaka M; Asayama K; Ishikura K; Obara T; Mano N; Ohkubo T; Imai Y Clin Exp Hypertens; 2014; 36(2):83-91. PubMed ID: 24625334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]